ArticleFrontiers in pharmacology2022
Risk Scoring System for Vancomycin-Associated Acute Kidney Injury.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 12 citations in OpenAlex.
- Vancomycin-associated acute kidney injury in patients with moderate CKD: a multicentre retrospective cohort study.JAC-antimicrobial resistance · 2026Article
- Risk of Acute Kidney Injury Associated With Nephrotoxic Burden in Hospitalized Patients: A Scoping Review.Clinical pharmacology and therapeutics · 2026Article
- Development and Validation of a Novel Scoring Model Integrating Clinical Risk Factors and Pharmacokinetic Parameters to Predict Vancomycin-Induced Nephrotoxicity.Pharmacotherapy · 2026Article
- Machine learning studies of drug-induced nephrotoxicity: a scoping review.Therapeutic advances in drug safety · 2026Article
- Risk Stratification for Vancomycin-Associated Acute Kidney Injury in Chinese Adult Inpatients: A Multicenter Retrospective Cohort Study.Infection and drug resistance · 2026Article
- Developing a prediction model of neonatal pneumonia in patients with gestational diabetes mellitus in primary medical institutions.Frontiers in pediatrics · 2026Article
- Clinical risk assessment of serum creatinine abnormalities during vancomycin therapy: a retrospective study using machine learning models.International journal of clinical pharmacy · 2025Article
- Towards a prescribing monitoring system for medication safety evaluation within electronic health records: a scoping review.BMC medical informatics and decision making · 2025Article
- An Ensemble Machine Learning Model for Early Prediction of Vancomycin-Induced Acute Kidney Injury in ICU Patients.Archives of academic emergency medicine · 2025Article
- Development and validation of a nomogram to predict the risk of vancomycin-related acute kidney injury in critical care patients.Frontiers in pharmacology · 2024Article
- Prediction of acute kidney injury in patients with liver cirrhosis using machine learning models: evidence from the MIMIC-III and MIMIC-IV.International urology and nephrology · 2024Article
- Vancomycin associated acute kidney injury in patients with infectious endocarditis: a large retrospective cohort study.Frontiers in pharmacology · 2023Article
- Pharmacokinetic assessment of vancomycin in critically ill patients and nephrotoxicity prediction using individualized pharmacokinetic parameters.Frontiers in pharmacology · 2022Article
- Analysis of a machine learning-based risk stratification scheme for acute kidney injury in vancomycin.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vancomycin-associated acute kidney injury (AKI) remains a major challenge for patients and clinicians. This study aimed to construct a risk scoring system for vancomycin-associated AKI. We retrospectively reviewed medical records of patients who underwent therapeutic drug monitoring for vancomycin from June 2018 to July 2019. We selected possible risk factors for AKI by univariate and multivariable logistic regression analyses and developed a scoring system for vancomycin-associated AKI. Machine learning methods were utilized to predict risk factors for the occurrence of AKI. The incidence of vancomycin-associated AKI was 31.7% among 104 patients included in this study. A bodyweight ≤60 kg (two points), a Charlson comorbidity index ≥3 (two points), a vancomycin trough serum level >15 μg/ml (one point), and concomitant use of ≥6 nephrotoxic agents (two points) were included to construct a risk scoring system based on the coefficient from the logistic regression model. The area under the receiver operating characteristic curve (AUROC) (mean, 95% confidence interval (CI)) across 10 random iterations using five-fold cross-validated multivariate logistic regression, elastic net, random forest, support vector machine (SVM)-linear kernel, and SVM-radial kernel models was 0.735 (0.638-0.833), 0.737 (0.638-0.835), 0.721 (0.610-0.833), 0.739 (0.648-0.829), and 0.733 (0.640-0.826), respectively. For total scores of 0-1, 2-3, 4-5, 6-7, the risk of vancomycin-associated AKI was 5, 25, 45, and 65%, respectively. Our scoring system can be applied to clinical settings in which several nephrotoxic agents are used along with vancomycin therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.